Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET. The live panel discussion can be accessed on Maxim’s M-Vest website. For more information and to sign up, please visit: https://m-vest.com/events/healthcare-10152024. About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 [Yahoo! Finance]Yahoo! Finance
- Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007GlobeNewswire
- Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Maxim Group from $60.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at HC Wainwright from $60.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire
BLTE
Earnings
- 11/12/24 - Beat
BLTE
Analyst Actions
- 11/15/24 - Maxim Group
BLTE
Sec Filings
- 11/20/24 - Form 144
- 11/19/24 - Form 144
- 11/12/24 - Form 6-K
- BLTE's page on the SEC website